MCID: CCK001
MIFTS: 59

Cockayne Syndrome malady

Categories: Genetic diseases, Rare diseases, Neuronal diseases, Eye diseases, Ear diseases, Skin diseases, Fetal diseases, Cancer diseases

Aliases & Classifications for Cockayne Syndrome

About this section
Sources:
10Disease Ontology, 68Wikipedia, 21GeneReviews, 45NIH Rare Diseases, 22GeneTests, 23Genetics Home Reference, 47Novoseek, 12DISEASES, 51Orphanet, 36MeSH, 65UMLS, 24GTR, 27ICD10, 42NCIt, 59SNOMED-CT, 28ICD10 via Orphanet, 37MESH via Orphanet, 66UMLS via Orphanet
See all MalaCards sources

Aliases & Descriptions for Cockayne Syndrome:

Name: Cockayne Syndrome 10 68 21 45 22 23 47 12 51 36 65
Dwarfism-Retinal Atrophy-Deafness Syndrome 68 45 23
Progeria-Like Syndrome 68 45 23
Cockayne's Syndrome 10 45 24
Progeroid Nanism 68 45 23
 
Cs 68 23
Dwarfism with Retinal Atrohpy and Deafness 22
Deafness-Dwarfism-Retinal Atrophy 22
Neill-Dingwall Syndrome 68

Characteristics:

Orphanet epidemiological data:

51
cockayne syndrome:
Inheritance: Autosomal recessive; Prevalence: 1-9/1000000 (Europe); Age of onset: All ages; Age of death: any age

Classifications:



External Ids:

Disease Ontology10 DOID:2962
ICD1027 Q87.1
MeSH36 D003057
NCIt42 C9460
SNOMED-CT59 205832003, 21086008
Orphanet51 191
ICD10 via Orphanet28 Q87.1
MESH via Orphanet37 D003057
UMLS via Orphanet66 C0009207
UMLS65 C0009207

Summaries for Cockayne Syndrome

About this section
NIH Rare Diseases:45 Cockayne syndrome is a rare condition which causes short stature, premature aging (progeria), severe photosensitivity, and moderate to severe learning delay. this syndrome also includes failure to thrive in the newborn, microcephaly, and impaired nervous system development. other symptoms may include hearing loss, tooth decay, and eye and bone abnormalities.  cockayne syndrome type 1 (type a) is sometimes called “classic” or "moderate" cockayne syndrome and is diagnosed during early childhood. cockayne syndrome type 2 (type b) is sometimes referred to as the “severe” or "early-onset" type. this more severe form presents with growth and developmental abnormalities at birth. the third type, cockayne syndrome type 3 (type c) is a milder form of the disorder. cockayne syndrome is caused by mutations in either the ercc8 (csa) or ercc6 (csb) genes and is inherited in an autosomal recessive pattern. the typical lifespan for individuals with cockayne syndrome type 1 is ten to twenty years. individuals with type 2 usually do not survive past childhood. those with type 3 live into middle adulthood. last updated: 10/26/2015

MalaCards based summary: Cockayne Syndrome, also known as dwarfism-retinal atrophy-deafness syndrome, is related to cockayne syndrome type ii and cockayne syndrome type iii, and has symptoms including microcephaly, abnormality of the nose and macrotia. An important gene associated with Cockayne Syndrome is ERCC8 (Excision Repair Cross-Complementation Group 8), and among its related pathways are Cyclophosphamide Pathway, Pharmacodynamics and RNA Polymerase I Promoter Escape. Affiliated tissues include eye, bone and brain, and related mouse phenotypes are pigmentation and adipose tissue.

Disease Ontology:10 An autosomal recessive disease that is caused by rare mutations in two DNA excision repair proteins, ERCC-8 and ERCC-6, and characterized by growth failure, impaired development of the nervous system, abnormal sensitivity to sunlight (photosensitivity), and premature aging.

Genetics Home Reference:23 Cockayne syndrome is a rare disorder characterized by short stature and an appearance of premature aging. Features of this disorder include a failure to gain weight and grow at the expected rate (failure to thrive), abnormally small head size (microcephaly), and impaired development of the nervous system. Affected individuals have an extreme sensitivity to sunlight (photosensitivity), and even a small amount of sun exposure can cause a sunburn. Other possible signs and symptoms include hearing loss, eye abnormalities, severe tooth decay, bone abnormalities, and changes in the brain that can be seen on brain scans.

Wikipedia:68 Cockayne syndrome (CS), also called Neill-Dingwall syndrome, is a rare autosomal recessive... more...

GeneReviews summary for NBK1342

Related Diseases for Cockayne Syndrome

About this section

Diseases in the Cockayne Syndrome family:

Cockayne Syndrome, Type a Cockayne Syndrome, Type B
Cockayne Syndrome Type I Cockayne Syndrome Type Ii
Cockayne Syndrome Type Iii Ercc6-Related Cockayne Syndrome
Ercc8-Related Cockayne Syndrome

Diseases related to Cockayne Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 292)
idRelated DiseaseScoreTop Affiliating Genes
1cockayne syndrome type ii34.2ERCC4, ERCC6, ERCC8
2cockayne syndrome type iii34.2ERCC1, ERCC6, ERCC8
3xeroderma pigmentosum, group b32.7ERCC2, ERCC3
4cerebrooculofacioskeletal syndrome 130.9ERCC6, ERCC8
5cerebrooculofacioskeletal syndrome 229.1ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6
6cockayne syndrome type i12.5
7cockayne syndrome, type b12.5
8cockayne syndrome, type a12.5
9ercc6-related cockayne syndrome12.3
10ercc8-related cockayne syndrome12.3
11xeroderma pigmentosum-cockayne syndrome complex12.2
12xeroderma pigmentosum, group f11.9
13cowden syndrome 111.7
14xeroderma pigmentosum, group g11.6
15epidermolysis bullosa simplex, weber-cockayne type11.4
16progeroid short stature with pigmented nevi11.2
17progeria-short stature-pigmented nevi syndrome11.2
18coenzyme q cytochrome c reductase deficiency of10.4ERCC6, ERCC8
19cerebrooculofacioskeletal syndrome 310.4
20xeroderma pigmentosum, group d10.4
21hyperammonemia due to n-acetylglutamate synthase deficiency10.4ERCC3, ERCC5
22leukemia10.3
23prostatitis10.3
24lung cancer10.3
25hepatitis10.3
26de sanctis-cacchione syndrome10.3ERCC2, ERCC5, ERCC6
27prostate cancer10.3
28retinitis10.3
29uv-sensitive syndrome 210.3
30cerebrooculofacioskeletal syndrome 410.3
31cataract-microcephaly-failure to thrive-kyphoscoliosis10.3
32cerebro-oculo-facio-skeletal syndrome10.3
33xfe progeroid syndrome10.2ERCC1, ERCC4
34dermatomyositis10.2
35melanoma10.2
36cerebritis10.2
37neuronitis10.2
38psoriasis10.2
39cardiomyopathy10.2
40aneurysm10.2
41trichothiodystrophy 1, photosensitive10.1ERCC2, ERCC3, XPC
42dry eye syndrome10.1ERCC2, XPA
43neuroblastoma10.1
44colorectal cancer10.1
45myocardial infarction10.1
46obesity10.1
47hepatitis c virus10.1
48essential tremor10.1
49chondrosarcoma10.1
50bipolar disorder10.1

Graphical network of the top 20 diseases related to Cockayne Syndrome:



Diseases related to cockayne syndrome

Symptoms for Cockayne Syndrome

About this section

Symptoms:

 51 (show all 61)
  • microcephaly
  • deepset eyes/enophthalmos
  • retinopathy
  • anomalies of nose and olfaction
  • multiple caries
  • long/large ear
  • sensorineural deafness/hearing loss
  • skin photosensitivity
  • vesicles/bullous/exsudative lesions/bullous/cutaneous/mucosal detachment
  • peripheral neuropathy
  • ataxia/incoordination/trouble of the equilibrium
  • hypertonia/spasticity/rigidity/stiffness
  • hypereflexia
  • intellectual deficit/mental/psychomotor retardation/learning disability
  • autosomal recessive inheritance
  • short stature/dwarfism/nanism
  • failure to thrive/difficulties for feeding in infancy/growth delay
  • premature ageing
  • dental malocclusion
  • retinal/chorioretinal dysplasia/dystrophy
  • strabismus/squint
  • hearing loss/hypoacusia/deafness
  • kyphosis
  • long limbs/dolichostenomelia
  • large hand
  • foot anomalies
  • skin hypoplasia/aplasia/atrophy
  • abnormal scarring/cheloids/hypertrophic scars
  • erythema/erythematous lesions/erythroderma/polymorphous erythema
  • diffuse/generalised skin hyperpigmentation/melanoderma
  • hypotrichosis/atrichia/atrichiasis/scalp hairlessness
  • fine hair
  • chronic arterial hypertension
  • renal/kidney anomalies
  • cortical atrophy without hydrocephaly/cerebral hemiatrophy/subcortical atrophy
  • intracranial/cerebral calcifications
  • nerve conduction abnormality
  • eeg anomalies
  • movement disorder
  • tremor
  • restricted joint mobility/joint stiffness/ankylosis
  • early death/lethality
  • anophthalmos/anophthalmia/microphthalmos/microphthalmia
  • cataract/lens opacification
  • retinitis pigmentosa/retinal pigmentary changes
  • optic nerve anomaly/optic atrophy/anomaly of the papilla
  • cleft lip and palate
  • high vaulted/narrow palate
  • delayed dentition/eruption of teeth/lack of eruption of teeth
  • breast tissue/mammary gland absence/aplasia
  • platyspondyly
  • pelvis anomaly/narrow/broad iliac wings/pubis abnormality
  • arthrogryposis
  • telangiectasiae of the skin
  • hair and scalp anomalies
  • cardiomyopathy/hypertrophic/dilated
  • renal glomerular defect/glomerulopathy
  • nephrotic syndrome
  • undescended/ectopic testes/cryptorchidia/unfixed testes
  • seizures/epilepsy/absences/spasms/status epilepticus
  • asthenia/fatigue/weakness

HPO human phenotypes related to Cockayne Syndrome:

(show all 52)
id Description Frequency HPO Source Accession
1 microcephaly hallmark (90%) HP:0000252
2 abnormality of the nose hallmark (90%) HP:0000366
3 macrotia hallmark (90%) HP:0000400
4 sensorineural hearing impairment hallmark (90%) HP:0000407
5 retinopathy hallmark (90%) HP:0000488
6 deeply set eye hallmark (90%) HP:0000490
7 carious teeth hallmark (90%) HP:0000670
8 cutaneous photosensitivity hallmark (90%) HP:0000992
9 hypertonia hallmark (90%) HP:0001276
10 hyperreflexia hallmark (90%) HP:0001347
11 incoordination hallmark (90%) HP:0002311
12 short stature hallmark (90%) HP:0004322
13 prematurely aged appearance hallmark (90%) HP:0007495
14 abnormal blistering of the skin hallmark (90%) HP:0008066
15 peripheral neuropathy hallmark (90%) HP:0009830
16 cognitive impairment hallmark (90%) HP:0100543
17 strabismus typical (50%) HP:0000486
18 chorioretinal abnormality typical (50%) HP:0000532
19 dental malocclusion typical (50%) HP:0000689
20 decreased nerve conduction velocity typical (50%) HP:0000762
21 hypertension typical (50%) HP:0000822
22 atypical scarring of skin typical (50%) HP:0000987
23 large hands typical (50%) HP:0001176
24 tremor typical (50%) HP:0001337
25 limitation of joint mobility typical (50%) HP:0001376
26 disproportionate tall stature typical (50%) HP:0001519
27 abnormality of the foot typical (50%) HP:0001760
28 cerebral cortical atrophy typical (50%) HP:0002120
29 fine hair typical (50%) HP:0002213
30 eeg abnormality typical (50%) HP:0002353
31 cerebral calcification typical (50%) HP:0002514
32 kyphosis typical (50%) HP:0002808
33 generalized hyperpigmentation typical (50%) HP:0007440
34 aplasia/hypoplasia of the skin typical (50%) HP:0008065
35 abnormal hair quantity typical (50%) HP:0011362
36 cryptorchidism occasional (7.5%) HP:0000028
37 nephrotic syndrome occasional (7.5%) HP:0000100
38 abnormality of the palate occasional (7.5%) HP:0000174
39 oral cleft occasional (7.5%) HP:0000202
40 cataract occasional (7.5%) HP:0000518
41 optic atrophy occasional (7.5%) HP:0000648
42 delayed eruption of teeth occasional (7.5%) HP:0000684
43 platyspondyly occasional (7.5%) HP:0000926
44 seizures occasional (7.5%) HP:0001250
45 hypertrophic cardiomyopathy occasional (7.5%) HP:0001639
46 abnormality of pelvic girdle bone morphology occasional (7.5%) HP:0002644
47 arthrogryposis multiplex congenita occasional (7.5%) HP:0002804
48 abnormality of retinal pigmentation occasional (7.5%) HP:0007703
49 aplasia/hypoplasia affecting the eye occasional (7.5%) HP:0008056
50 telangiectasia of the skin occasional (7.5%) HP:0100585
51 breast aplasia occasional (7.5%) HP:0100783
52 glomerulopathy occasional (7.5%) HP:0100820

Drugs & Therapeutics for Cockayne Syndrome

About this section

FDA approved drugs:

id Drug Name Active Ingredient(s)15 Company Approval Date
1
Provenge15 41 sipuleucel-T Dendreon May 2010
FDA Label: Provenge
Disease/s that Drug Treats:hormone refractory prostate cancer
Indications and Usage:15 PROVENGE is an autologous cellularimmunotherapy indicated for the treatment ofasymptomatic or minimally symptomatic metastaticcastrate resistant (hormone refractory) prostatecancer. (1)
DrugBank Targets: -
Mechanism of Action:15 
Target: PAP
Action: inducer of immune response against this antigen expressed in most prostate cancers
FDA: PROVENGE is classified as an autologous cellular immunotherapy. While the precisemechanism of action is unknown, PROVENGE is designed to induce an immune responsetargeted against PAP, an antigen expressed in most prostate cancers. During ex vivo culturewith PAP-GM-CSF, APCs take up and process the recombinant target antigen into smallpeptides that are then displayed on the APC surface.In Study 1, 237 out of the 512 patients randomized were evaluated for the development ofhumoral and T cell immune responses (proliferative and gamma-interferon (γIFN) ELISPOT)to the target antigens at Baseline, and at Weeks 6, 14, and 26. Antibody (IgM and IgG)responses against PAP-GM-CSF and PAP antigen alone were observed through thefollow-up period in the PROVENGE group. Neutralizing antibody responses to GM-CSFwere transient. T cell proliferative and γIFN ELISPOT responses to PAP-GM-CSF fusionprotein were observed in cells collected from peripheral blood of patients through thefollow-up period in the PROVENGE treatment group but not in controls. In some patients aresponse to PAP antigen alone was observed. No conclusions could be made regarding theclinical significance of the observed immune responses.
2
Oralair15 Greer Labs April 2014
FDA Label: -
Disease/s that Drug Treats:grass pollen-induced allergic rhinitis with or without conjunctivitis
Indications and Usage:15 -
DrugBank Targets: -
Mechanism of Action:15 
Target: -
Action: -
FDA: -

Drugs for Cockayne Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

idNameStatusPhaseClinical TrialsCas NumberPubChem Id
1
Mannitolapproved, investigationalPhase 1, Phase 224269-65-8453, 6251
Synonyms:
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexaol
(2R,3R,4R,5R)-Hexane-1,2,3,4,5,6-hexol
(2R,3R,4R,5R)-hexane-1,2,3,4,5,6-hexol
(L)-Mannitol
1,2,3,4,5,6-Hexanehexol
123897-58-5
133-43-7
15719_ALDRICH
15719_RIEDEL
33440_RIEDEL
33440_SIGMA
36413-61-3
4-01-00-02841 (Beilstein Handbook Reference)
5149-40-6
63559_FLUKA
63559_SIGMA
63560_FLUKA
63565_FLUKA
63565_SIGMA
69-65-8
75398-80-0
85085-15-0
87-78-5
AB1002081
AC-12776
AC1L1M49
AC1Q28E5
AI3-19511
AR-1J3861
Ambap69-65-8
BRN 1721898
C00392
C6H14O6
CCRIS 369
CHEBI:16899
CHEMBL689
CID6251
Cordycepate
Cordycepic acid
D-(-)-Mannitol
D-Mannitol
D-Mannitol (JP15)
D-mannite
D-mannitol
D00062
D008353
DL-Mannitol
Diosmol
ED1D1E61-FEFB-430A-AFDC-D1F4A957FC3D
EINECS 200-711-8
EINECS 201-770-2
Fraxinine
HSDB 714
Hexahydroxyhexane
Hexanhexol
Invenex
Isotol
LS-1588
LS-89250
M0044
M1902_SIGMA
M4125_SIAL
M8429_SIAL
M9546_SIAL
M9647_SIAL
MANNITOL 10% W/ DEXTROSE 5% IN DISTILLED WATER
MANNITOL 15% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.45%
 
MANNITOL 25%
MANNITOL 5% W/ DEXTROSE 5% IN SODIUM CHLORIDE 0.12%
MLS001335977
MLS001335978
MTL
Manicol
Manitol
Maniton S
Maniton-S
Manna Sugar
Manna sugar
Mannazucker
Mannidex
Mannidex 16700
Mannigen
Mannistol
Mannit
Mannit p
Mannite
Mannitol
Mannitol (USP)
Mannitol (VAN)
Mannitol 10%
Mannitol 10% In Plastic Container
Mannitol 15%
Mannitol 15% In Plastic Container
Mannitol 20%
Mannitol 20% In Plastic Container
Mannitol 5%
Mannitol 5% In Plastic Container
Mannitol [USAN]
Mannitolum
Mannogem 2080
Marine Crystal
Marine crystal
MolPort-003-927-039
Mushroom sugar
NCGC00164246-01
NCI-C50362
NSC 407017
NSC 9256
OSMITROL 10% IN WATER IN PLASTIC CONTAINER
OSMITROL 15% IN WATER IN PLASTIC CONTAINER
OSMITROL 20% IN WATER IN PLASTIC CONTAINER
OSMITROL 5% IN WATER IN PLASTIC CONTAINER
Osmitrol
Osmitrol (TN)
Osmitrol 10% In Water
Osmitrol 15% In Water
Osmitrol 20% In Water
Osmitrol 5% In Water
Osmofundin
Osmosal
Resectisol
Resectisol In Plastic Container
SDM No. 35
SMR000857324
SORBITOL-MANNITOL IN PLASTIC CONTAINER
Sorbitol-Mannitol
TL806434
UNII-3OWL53L36A
ZINC02041302
bmse000099
cpd without stereochemical designation
e 421
e-421
e421
manita
mannitol
2Pharmaceutical SolutionsPhase 1, Phase 27004

Interventional clinical trials:

idNameStatusNCT IDPhase
1Pharmacokinetics and Safety Study of Single and Multiple Oral Doses Prodarsan™ in Patients With Cockayne SyndromeCompletedNCT01142154Phase 1, Phase 2
2Examination of Clinical and Laboratory Abnormalities in Patients With Defective DNA Repair: Xeroderma Pigmentosum, Cockayne Syndrome, or TrichothiodystrophyRecruitingNCT00001813
3Observational Study to Assess Natural History in Cockayne Syndrome PatientsTerminatedNCT00985413

Search NIH Clinical Center for Cockayne Syndrome


Cochrane evidence based reviews: cockayne syndrome

Genetic Tests for Cockayne Syndrome

About this section

Genetic tests related to Cockayne Syndrome:

id Genetic test Affiliating Genes
1 Cockayne Syndrome22 ERCC8

Anatomical Context for Cockayne Syndrome

About this section

MalaCards organs/tissues related to Cockayne Syndrome:

33
Eye, Bone, Brain, Skin, Prostate, Breast, T cells

Animal Models for Cockayne Syndrome or affiliated genes

About this section

MGI Mouse Phenotypes related to Cockayne Syndrome:

38 (show all 14)
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00011869.1ERCC2, HELLS, HPRT1, XPA
2MP:00053759.1ERCC1, ERCC2, ERCC6, HELLS, XPA
3MP:00053918.7ERCC2, ERCC6, ERCC8, HPRT1, XPA, XPC
4MP:00053708.3ERCC1, ERCC4, ERCC5, ERCC6, HPRT1, TCEA1
5MP:00020068.2ERCC1, ERCC2, ERCC3, ERCC6, ERCC8, HPRT1
6MP:00053867.6ERCC1, ERCC2, ERCC3, ERCC6, ERCC8, HELLS
7MP:00107717.5ERCC1, ERCC2, ERCC3, ERCC5, ERCC6, ERCC8
8MP:00053877.4ERCC1, ERCC2, ERCC5, ERCC6, ERCC8, HELLS
9MP:00053847.3ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, ERCC8
10MP:00053977.2ERCC1, ERCC2, ERCC5, ERCC6, ERCC8, HELLS
11MP:00053766.9ERCC1, ERCC2, ERCC5, ERCC6, ERCC8, HELLS
12MP:00107686.3ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6
13MP:00053786.3ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6

Publications for Cockayne Syndrome

About this section

Articles related to Cockayne Syndrome:

(show top 50)    (show all 367)
idTitleAuthorsYear
1
Recurrent intracranial neurenteric cyst with malignant transformation: A case report and literature review. (27123123)
2016
2
Association of the +331G/A progesterone receptor gene (PgR) polymorphism with risk of endometrial cancer in Caucasian women: a meta-analysis. (25037596)
2015
3
The diagnosis and management of hiatus hernia. (25341679)
2014
4
Percutaneous core needle biopsies: The yield in spinal tuberculosis. (24388083)
2014
5
Refractory Open Angle Glaucoma after Nd:YAG Laser Lysis of Vitreous Floaters. (25308785)
2014
6
Clinical significance of therapy using branched-chain amino acid granules in patients with liver cirrhosis and hepatocellular carcinoma. (23819582)
2013
7
Further insights into the role of the annexin A5 M2 haplotype as recurrent pregnancy loss factor, assessing timing of miscarriage and partner risk. (23899942)
2013
8
Control of histone H3 lysine 9 (H3K9) methylation state via cooperative two-step demethylation by Jumonji domain containing 1A (JMJD1A) homodimer. (24214985)
2013
9
Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. (21685941)
2012
10
Severe acute respiratory syndrome (SARS) and the rhetorical construction of "bad" scientific work. (22586846)
2012
11
Bromelain-induced apoptosis in GI-101A breast cancer cells. (22191568)
2012
12
A case of long-term survival after pulmonary resection for metachronous pulmonary metastasis of basaloid squamous cell carcinoma of the esophagus. (22721697)
2012
13
Calciphylaxis in a patient with acute kidney injury and alcoholic cirrhosis. (22105455)
2011
14
Waking up to narcolepsy. (21866561)
2011
15
Investigating contamination of phytotherapy products for benign prostatic hyperplasia with alpha-blockers and 5alpha-reductase inhibitors. (20303529)
2010
16
Inhibitory effect of cucurbitacin E on pancreatic cancer cells growth via STAT3 signaling. (19816711)
2010
17
Case report: autofluorescence imaging and phenotypic variance in a sibling pair with early-onset retinal dystrophy due to defective CRB1 function. (19401883)
2009
18
Regulation of hypoxia-inducible genes by ETS1 transcription factor. (18381358)
2008
19
Common variable immunodeficiency: an update on etiology and management. (18424338)
2008
20
Evaluation of topoisomerase IIa expression in pancreatic ductal adenocarcinoma: a pilot study using chromogenic in situ hybridization and immunohistochemistry on tissue microarrays. (17449965)
2007
21
Hypoxic condition- and high cell density-induced expression of Redd1 is regulated by activation of hypoxia-inducible factor-1alpha and Sp1 through the phosphatidylinositol 3-kinase/Akt signaling pathway. (17307335)
2007
22
Topologies of a substrate protein bound to the chaperonin GroEL. (17499047)
2007
23
In vitro and in vivo characteristics of frozen/thawed neonatal pig split-skin strips: a novel biologically active dressing for areas of severe, acute or chronic skin loss. (17203198)
2007
24
Comparison of methods for determining zeta-chain associated protein - 70 (ZAP-70) expression in patients with B-cell chronic lymphocytic leukemia (B-CLL). (16906577)
2006
25
Autologous blood pre-donation and perioperative use of erythropoietin]. (17265804)
2006
26
Understanding and negotiating friendships: perspectives from an adolescent with Asperger syndrome. (17088277)
2006
27
Liquid chromatography-tandem mass spectroscopy assay for quercetin and conjugated quercetin metabolites in human plasma and urine. (15925552)
2005
28
Activated STAT 3 in choroidal neovascular membranes of patients with age-related macular degeneration. (16088240)
2005
29
Molecular analysis of HLA allele frequencies and haplotypes in Baloch of Iran compared with related populations of Pakistan. (15496201)
2004
30
Pulse wave encephalopathy: a spectrum hypothesis incorporating Alzheimer's disease, vascular dementia and normal pressure hydrocephalus. (14962623)
2004
31
The human papillomavirus 16 E6 protein binds to Fas-associated death domain and protects cells from Fas-triggered apoptosis. (15073179)
2004
32
Low-affinity receptor-mediated induction of superoxide by N-formyl-methionyl-leucyl-phenylalanine and WKYMVm in IMR90 human fibroblasts. (14744631)
2004
33
Mammalian class Sigma glutathione S-transferases: catalytic properties and tissue-specific expression of human and rat GSH- dependent prostaglandin D2 synthases. (11672424)
2001
34
The influence of hemodynamic stress factors on intracranial aneurysm formation. (11702865)
2001
35
Expression of glypican 3 (GPC3) in embryonal tumors. (11008203)
2000
36
An association study between alcoholism and the serotonergic receptor genes. (10776672)
2000
37
Constitutive expression of stromal derived factor-1 by mucosal epithelia and its role in HIV transmission and propagation. (10744978)
2000
38
Delirium associated with vitamin B12 deficiency after pneumonia. (10626095)
1999
39
Case report: necrotic glossitis and sinusitis in a cow caused apparently by a Fusobacterium necrophorum like microorganism. (9674310)
1998
40
Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. (9275025)
1997
41
Inhibition of stromelysin-1 (MMP-3) by P1'-biphenylylethyl carboxyalkyl dipeptides. (9083493)
1997
42
Transforming growth factors-beta s: a multifunctional cytokine family. Implication in the regulation of adrenocortical cell endocrine functions. (8964588)
1996
43
Somatic mosaicism of CAG repeat in dentatorubral-pallidoluysian atrophy (DRPLA). (7633415)
1995
44
Malignant histiocytosis in childhood: a distinctive CD30-positive clinicopathological entity associated with a chromosomal translocation involving 5q35. (1313990)
1992
45
Effect of short-term fasting treatment on liver and renal function. (1344010)
1992
46
Changes in sex hormone binding globulin, high density lipoprotein cholesterol and plasma lipids in male cyclists during training and competition. (1735419)
1992
47
Carotid pseudoaneurysm simulating Pancoast tumor. (6607632)
1984
48
Keratoconus and acute hydrops in mentally retarded patients with congenital rubella syndrome. (7468739)
1981
49
Periarteritis nodosa: clinical manifestations, diagnostic clues, and histopathological findings; case report. (13358064)
1956
50

Variations for Cockayne Syndrome

About this section

Expression for genes affiliated with Cockayne Syndrome

About this section
Search GEO for disease gene expression data for Cockayne Syndrome.

Pathways for genes affiliated with Cockayne Syndrome

About this section

Pathways related to Cockayne Syndrome according to GeneCards Suite gene sharing:

idSuper pathwaysScoreTop Affiliating Genes
1
Show member pathways
9.9ERCC1, ERCC4
2
Show member pathways
9.7ERCC2, ERCC3, ERCC6
39.2ERCC2, ERCC3, XPA, XPC
48.7ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, XPA
5
Show member pathways
7.9ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6
6
Show member pathways
7.9ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6
7
Show member pathways
6.5ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6
8
Show member pathways
6.5ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, ERCC6

GO Terms for genes affiliated with Cockayne Syndrome

About this section

Biological processes related to Cockayne Syndrome according to GeneCards Suite gene sharing:

(show all 26)
idNameGO IDScoreTop Affiliating Genes
1transcription from RNA polymerase I promoterGO:000636010.4ERCC2, ERCC3
2nucleotide-excision repair involved in interstrand cross-link repairGO:190125510.4ERCC4, XPA
3embryonic organ developmentGO:004856810.4ERCC1, ERCC3
4termination of RNA polymerase I transcriptionGO:000636310.3ERCC2, ERCC3
5transcription elongation from RNA polymerase I promoterGO:000636210.3ERCC2, ERCC3
6intrinsic apoptotic signaling pathway in response to DNA damageGO:000863010.2ERCC6, XPA
7transcription elongation from RNA polymerase II promoterGO:000636810.2ERCC2, TCEA1
8response to auditory stimulusGO:001099610.2XPA, XPC
9positive regulation of viral transcriptionGO:005043410.2ERCC2, TCEA1
10nucleotide-excision repair, DNA incision, 5-to lesionGO:000629610.1ERCC3, ERCC4, ERCC5
11lymphocyte proliferationGO:004665110.0HELLS, HPRT1
12response to UVGO:000941110.0ERCC2, ERCC3, ERCC6
13UV-damage excision repairGO:007091410.0XPA, XPC
14multicellular organism growthGO:003526410.0ERCC1, ERCC2, ERCC6
15nucleotide-excision repairGO:00062899.8ERCC1, ERCC4, ERCC8
16nucleotide-excision repair, preincision complex assemblyGO:00062949.7ERCC3, XPA, XPC
17nucleotide-excision repair, DNA incision, 3-to lesionGO:00062959.7ERCC1, ERCC3, ERCC4
18nucleotide-excision repair, DNA duplex unwindingGO:00007179.6ERCC2, ERCC3
19UV protectionGO:00096509.6ERCC1, ERCC2, ERCC3, ERCC4, ERCC5
20cellular response to DNA damage stimulusGO:00069749.3ERCC1, ERCC6, ERCC8, XPC
21global genome nucleotide-excision repairGO:00709119.3ERCC1, ERCC2, ERCC3, XPA
22response to oxidative stressGO:00069799.2ERCC1, ERCC2, ERCC3, ERCC6, XPA
23nucleotide-excision repair, preincision complex stabilizationGO:00062939.1ERCC1, ERCC2, ERCC3, ERCC4, ERCC5, XPA
24nucleotide-excision repair, DNA incisionGO:00336838.8ERCC1, ERCC2, ERCC4, ERCC5, XPA
25transcription-coupled nucleotide-excision repairGO:00062837.5ERCC1, ERCC2, ERCC3, ERCC4, ERCC6, ERCC8
26DNA repairGO:00062816.8ERCC2, ERCC3, ERCC4, ERCC5, ERCC6, ERCC8

Molecular functions related to Cockayne Syndrome according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1nuclease activityGO:000451810.2ERCC4, ERCC5
2DNA-dependent ATPase activityGO:000809410.0ERCC2, ERCC3
3protein C-terminus bindingGO:00080229.9ERCC1, ERCC3, ERCC4
4single-stranded DNA bindingGO:00036979.4ERCC1, ERCC4, ERCC5, XPC
5DNA bindingGO:00036779.3ERCC3, ERCC4, ERCC6, XPC

Sources for Cockayne Syndrome

About this section
2CDC
14ExPASy
15FDA
16FMA
24GTR
25HGMD
26HMDB
27ICD10
28ICD10 via Orphanet
29ICD9CM
30IUPHAR
31KEGG
34MedGen
36MeSH
37MESH via Orphanet
38MGI
41NCI
42NCIt
43NDF-RT
46NINDS
47Novoseek
49OMIM
50OMIM via Orphanet
54PubMed
55QIAGEN
60SNOMED-CT via Orphanet
64Tumor Gene Family of Databases
65UMLS
66UMLS via Orphanet